Background
“Combination products” are comprised of two or more different types of products (i.e., a combination of a drug, device, and/or biological product). The drugs, devices, and biological products included in a combination product are referred to as its “constituent parts.” For review purposes, a combination product is assigned to a lead agency center (i.e., the Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), or Center for Devices and Radiological Health (CDRH)) based on a determination of the “primary mode of action” (PMOA) of the combination product.
The Prescription Drug User Fee Act of 1992 (PDUFA) added sections 735 and 736 to the Federal Food, Drug, and Cosmetic Act (FDCA), and authorized FDA to collect user fees from persons that submit applications for certain human drug and biological products. Medical device user fees were established by the Medical Device User Fee and Modernization Act (MDUFA). Application fees submitted under the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Amendments (BsUFA) are not addressed by this guidance.
Multiple Applications & Multiple User Fees?
As in the 2005 version of the guidance that it replaces, the 2024 guidance addresses how FDA applies user fees for combination products when separate applications are submitted for the constituent parts (such as may be the case when the constituent parts may be commercialized and used individually and not as part of a combination product). The revised guidance states that if an applicant submits two applications for a cross-labeled combination product, “each would be assessed the applicable user fee for each application.” But, FDA clarifies that “[f]or most combination products, one application is appropriate.”
In cases where FDA determines that a single application is not appropriate for the combination product and separate applications are needed, the agency says it will consider both applications in assessing user fee factors, spotlighting in this revised the guidance the various exceptions and reductions available to application user fees.
User Fee Exemptions
The guidance contains these helpful summaries depicting waivers, reductions, and exceptions available for PDUFA and MDUFA application fees:
The revised guidance also spells out the updated procedures for petitioning FDA for these waivers/reductions in application user fees.
Barrier to Innovation Waiver
FDA’s revised guidance devotes particular attention to explaining PDUFA’s “barrier to innovation” waiver (row two in the first table above), under which FDA says it will reduce application user fees “if the combination product is innovative and the applicant has limited resources or other circumstances.” If the combination product is innovative and the applicant does not have limited resources, “other circumstances” may be present if two applications are required, in which case FDA will reduce the user fees as follows:
-
Products requiring a MDUFA application and a PDUFA application: An applicant would be assessed the MDUFA application fee associated with the type of MDUFA application, and a PDUFA application fee reduced by the assessed MDUFA application fee [MDUFA + (PDUFA-MDUFA)]. The total amount assessed would be equivalent to one PDUFA application fee.
-
Products requiring two PDUFA applications: In the case where two full PDUFA fees would otherwise be assessed, the total amount assessed would be equivalent to one PDUFA application fee.
The guidance provides examples for when FDA would deem a medical product “innovative” under the PDUFA “barrier to innovation” provision, including when:
-
The combination product demonstrates new, progressive methods and forward-thinking in the treatment or diagnosis of disease or is at the forefront of new medical technology.”
-
There are no comparable alternatives for treatment, prevention, or diagnosis available in the U.S. market.
-
The combination product introduces a unique or superior method for diagnosing, curing, mitigating, treating, or preventing disease.
-
The combination product includes a new molecular entity or biological product, receives priority review designation, breakthrough therapy designation (as a drug/biological product), fast track designation, regenerative medicine advanced therapy (RMAT) designation, or breakthrough device designation. We have previously analyzed these expedited review pathways online here and here.
If you have any questions on how FDA may regulate a certain product, or on approval standards for drugs and medical devices more generally, please contact any of the authors of this alert or the Hogan Lovells attorney with whom you generally work.